

Form PTO-1449 FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE CITATION		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2945-A		SERIAL NO. 09/602,351	
<div style="position: relative; height: 100px;"> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; font-size: 24px; line-height: 1;"> O I P E FEB 12 2002 PATENT & TRADEMARK OFFICE </div> <div style="position: absolute; top: 50%; left: 50%; transform: translate(-50%, -50%); font-size: 12px;"> (Use several sheets if necessary) </div> </div>				APPLICANT Barbara K. Finck et al.		FILING DATE June 23, 2000	
				GROUP 1647			
U.S. PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
DR		Barker, JNWN et al., "Marked synergism between tumor necrosis factor- α and interferon- γ in regulation of keratinocyte-derived adhesion molecules and chemotactic factors," <i>J Clin Invest</i> 85:605-608, 1990.					
		Griffiths, CEM et al., "Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF- α) in allergic contact dermatitis (rhus dermatitis)," <i>Br J Dermatol</i> 124:519-526, 1991.					
		Groves, RW et al., "Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression," <i>Br J Dermatol</i> 132:345-352, 1995.					
		Linden, KG and Weinstein, GD, "Psoriasis: current perspectives with an emphasis on treatment," <i>Am J Med</i> 107:595-605, 1999.					
DR		Mease, P et al., "ENBREL® (etanercept) in patients with psoriatic arthritis and psoriasis," <i>Arthritis Rheum</i> 42 (9 Suppl):S377, 1999.					
EXAMINER				DATE CONSIDERED			
<i>David Romeo 4/20/2</i>							

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.